Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: Electric cardioversion has been successfully used in terminating symptomatic atrial fibrillation (AF). Nevertheless, large-scale study about the acute cardiovascular events following electrical cardioversion of AF is lacking. This study was performed to evaluate the incidence, risk factors, and clinical consequences of acute cardiovascular events following electrical cardioversion of AF. Materials and Methods: The study enrolled 1100 AF patients (mean age 60±11 years) who received cardioversion at four tertiary hospitals. Hospitalizations for stroke/transient ischemic attack, major bleedings, and arrhythmic events during 30 days post electriccardioversion were assessed. Results: The mean duration of anticoagulation before cardioversion was 95.8±51.6 days. The mean International Normalized Ratioat the time of cardioversion was 2.4±0.9. The antiarrhythmic drugs at the time of cardioversion were class I (45%), amiodarone (40%), beta-blocker (53%), calcium-channel blocker (21%), and other medication (11%). The success rate of terminating AF via cardioversion was 87% (n=947). Following cardioversion, 5 strokes and 5 major bleedings occurred. The history of stroke/transient ischemic attack (OR 6.23, 95% CI 1.69–22.90) and heart failure (OR 6.40, 95% CI 1.77–23.14) were among predictors of thromboembolicor bleeding events. Eight patients were hospitalized for bradyarrhythmia. These patients were more likely to have had a lower heart rate prior to the procedure (p=0.045). Consequently, 3 of these patients were implanted with a permanent pacemaker. Conclusion: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to preventthe cardiovascular events, several risk factors should be considered before cardioversion.
Abstract
Purpose: Electric cardioversion has been successfully used in terminating symptomatic atrial fibrillation (AF). Nevertheless, large-scale study about the acute cardiovascular events following electrical cardioversion of AF is lacking. This study was performed to evaluate the incidence, risk factors, and clinical consequences of acute cardiovascular events following electrical cardioversion of AF. Materials and Methods: The study enrolled 1100 AF patients (mean age 60±11 years) who received cardioversion at four tertiary hospitals. Hospitalizations for stroke/transient ischemic attack, major bleedings, and arrhythmic events during 30 days post electriccardioversion were assessed. Results: The mean duration of anticoagulation before cardioversion was 95.8±51.6 days. The mean International Normalized Ratioat the time of cardioversion was 2.4±0.9. The antiarrhythmic drugs at the time of cardioversion were class I (45%), amiodarone (40%), beta-blocker (53%), calcium-channel blocker (21%), and other medication (11%). The success rate of terminating AF via cardioversion was 87% (n=947). Following cardioversion, 5 strokes and 5 major bleedings occurred. The history of stroke/transient ischemic attack (OR 6.23, 95% CI 1.69–22.90) and heart failure (OR 6.40, 95% CI 1.77–23.14) were among predictors of thromboembolicor bleeding events. Eight patients were hospitalized for bradyarrhythmia. These patients were more likely to have had a lower heart rate prior to the procedure (p=0.045). Consequently, 3 of these patients were implanted with a permanent pacemaker. Conclusion: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to preventthe cardiovascular events, several risk factors should be considered before cardioversion.
참고문헌 (28)
- European Heart Rhythm Association, "Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)", Europace, 12, pp.1360~1420 (2010)
- Kannel WB, "Epidemiologic features of chronic atrial fibrillation: the Framingham study", N Engl J Med, 306, pp.1018~1022 (1982)
- Halperin JL, "Atrial fibrillation and stroke: new ideas, persisting dilemmas", Stroke, 19, pp.937~941 (1988)
- Wolf PA, "Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study", Arch Intern Med, 147, pp.1561~1564 (1987)
- American College of Cardiology Foundation, "Management of patients with atrial fibrillation (compilation of 2006 ACCF", AHA, AHA, pp.HRS recommendations): a report of the American College of Cardiology, American Heart Association Task Force on practice guidelines[DOI]
- Lown B, "“Cardioversion”of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients", N Engl J Med, 269, pp.325~331 (1963)
- Paul MH, "External electrical termination of supraventricular arrhythmias in congenital heart disease", Circulation, 25, pp.604~609 (1962)
- Bjerkelund CJ, "The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation", Am J Cardiol, 23, pp.208~216 (1969)
- Jensen JB, "Electroshock for atrial flutter and atrial fibrillation. Follow-up studies on 50 patients", JAMA, 194, pp.1181~1184 (1965)
- Weinberg DM, "Anticoagulation for cardioversion of atrial fibrillation", Am J Cardiol, 63, pp.745~746 (1989)
- Arnold AZ, "Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter", J Am Coll Cardiol, 19, pp.851~855 (1992)
- Resnekov L, "Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion", Br Heart J, 29, pp.926~936 (1967)
- January CT, "2014 AHA", ACC, American Heart Association Task Force on practice guidelines and the Heart Rhythm Society, pp.Circulation, 2014[DOI]
- Gentile F, "Safety of electrical cardioversion in patients with atrial fibrillation", Mayo Clin Proc, 77, pp.897~904 (2002)
- Gallagher MM, "Arrhythmic complications of electrical cardioversion: relationship to shock energy", Int J Cardiol, 123, pp.307~312 (2008)
- Grönberg T, "Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study", Europace, 15, pp.1432~1435 (2013)
- Airaksinen KE, "Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study", J Am Coll Cardiol, 62, pp.1187~1192 (2013)
- Zoll PM, "Termination of ventricular fibrillation in man by externally applied electric countershock", N Engl J Med, 254, pp.727~732 (1956)
- Lown B, "New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge", JAMA, 182, pp.548~555 (1962)
- Roy D, "Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation", Am Heart J, 112, pp.1039~1043 (1986)
- Klein AL, "Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation", N Engl J Med, 344, pp.1411~1420 (2001)
- Nagarakanti R, "Dabigatran versus warfarin in patients with atrial fibrillation:an analysis of patients undergoing cardioversion", Circulation, 123, pp.131~136 (2011)
- Suzuki S, "Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation", Circ J, 71, pp.761~765 (2007)
- JCS Joint Working Group, "Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version", Circ J, 74, pp.2479~2500 (2010)
- Yamaguchi T, "Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation:a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group", Stroke, 31, pp.817~821 (2000)
- Pisters R, "Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation:the Euro Heart Survey", Europace, 14, pp.666~674 (2012)
- Morani G, "Outpatient electrical cardioversion of atrial fibrillation:8 years’ experience. Analysis of shock-related arrhythmias", Pacing Clin Electrophysiol, 32, pp.1152~1158 (2009)
- Botkin SB, "Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs", Am Heart J, 145, pp.233~238 (2003)